How are patients’ preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn’s disease patients

References

• D’Haens G, Baert F, van Assche G, North-Holland Gut Club, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371(9613):660–667.
   PubMed Web of Science ®Google Scholar
• D’Haens GR, Panaccione R, Higgins PDR, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106(2):199–212.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Minerva Gastroenterol Dietol. 2010;56(2):233–243.
   PubMedGoogle Scholar
• Fiorino G, Szabò H, Fries W, et al. Adalimumab in Crohn’s disease: tips and tricks after 5 years of clinical experience. Curr Med Chem. 2011;18(8):1230–1238.
   PubMed Web of Science ®Google Scholar
• Ng SC, Plamondon S, Gupta A, et al. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas. Aliment Pharmacol Ther. 2009;30(7):757–766.
   PubMed Web of Science ®Google Scholar
• Sherman M, Tsynman DN, Kim A, et al. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy. J Digest Dis. 2014;15(4):174–179.
   PubMed Web of Science ®Google Scholar
• Vogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol. 2009;2:101–109.
   PubMedGoogle Scholar
• Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti–tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–333.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117(4):761–769.
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJH, et al. A Short-Term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med. 1997;337(15):1029–1036.
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340(18):1398–1405.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232–1239.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6(6):644–653.
   PubMed Web of Science ®Google Scholar
• Zorzi F, Zuzzi S, Onali S, et al. Efficacy and safety of infliximab and adalimumab in Crohn’s disease: a single Centre study. Aliment Pharmacol Ther. 2012;35(12):1397–1407.
   PubMed Web of Science ®Google Scholar
• Kestens C, van Oijen MGH, Mulder CLJ, et al. Adalimumab and infliximab are equally effective for Crohn’s disease in patients not previously treated with anti-tumor necrosis factor-α agents. Clin Gastroenterol Hepatol. 2013;11(7):826–831.
   PubMed Web of Science ®Google Scholar
• Billioud V, Laharie D, Filippi J, et al. Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience. Inflamm Bowel Dis. 2011;17(1):152–159.
   PubMed Web of Science ®Google Scholar
• Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients. Adv Therapy. 2009;26(10):936–946.
   PubMed Web of Science ®Google Scholar
• Allen PB, Lindsay H, Tham TCK. How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol. 2010;10:1.
   PubMed Web of Science ®Google Scholar
• Almario CV, Keller MS, Chen M, et al. Optimizing selection of biologics in inflammatory bowel disease: development of an online patient decision aid using conjoint analysis. Am J Gastroenterol. 2018;113(1):58–71.
   PubMed Web of Science ®Google Scholar
• Cha JM, Park DI, Park SH, et al. Physicians should provide shared Decision-Making for anti-TNF therapy to inflammatory bowel disease patients. J Korean Med Sci. 2017;32(1):85–94.
   PubMed Web of Science ®Google Scholar
• Gray JR, Leung E, Scales J. Treatment of ulcerative colitis from the patient's perspective: a survey of preferences and satisfaction with therapy. Aliment Pharmacol Ther. 2009;29(10):1114–1120.
   PubMed Web of Science ®Google Scholar
• Gregor JC, Williamson M, Dajnowiec D, et al. Inflammatory bowel disease patients prioritize mucosal healing, symptom control, and pain when choosing therapies: results of a prospective cross-sectional willingness-to-pay study. Patient Prefer Adherence. 2018;12:505–513.
   PubMed Web of Science ®Google Scholar
• Kariburyo MF, Xie L, Teeple A, et al. Predicting pre-emptive discussions of biologic treatment: results from an openness and preference survey of inflammatory bowel disease patients and their prescribers. Adv Ther. 2017;34(6):1398–1410.
   PubMed Web of Science ®Google Scholar
• Kim ES, Kim KO, Jang BI, et al. Factors contributing to the preference of Korean patients with Crohn’s disease when selecting an anti-tumor necrosis factor agent (CHOICE study). Gut Liver. 2016;10(3):391–398.
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Bentele N, Scharl M, et al. Systematic assessment of factors influencing preferences of Crohn’s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL) ). Inflamm Bowel Dis. 2012;18(8):1523–1530.
   PubMed Web of Science ®Google Scholar
• Canavan C, Abrams KR, Hawthorne B, et al. Long-term prognosis in Crohn’s disease: factors that affect quality of life. Aliment Pharmacol Ther. 2006;23(3):377–385.
   PubMed Web of Science ®Google Scholar
• López Blanco B, Moreno-Jiménez B, Devesa Múgica JM, et al. Relationship between socio-demographic and clinical variables, and health-related quality of life in patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2005;97(12):887–898.
   PubMedGoogle Scholar
• Blondel-Kucharski F, Chircop C, Marquis P, et al. Health-related quality of life in Crohn’s disease: a prospective longitudinal study in 231 patients. Am J Gastroenterology. 2001;96(10):2915–2920.
   PubMed Web of Science ®Google Scholar
• Teutsch C. Patient-doctor communication. Med Clin North Am. 2003;87(5):1115–1145.
   PubMed Web of Science ®Google Scholar
• Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114(1):39–43.
   PubMed Web of Science ®Google Scholar
• Clark MD, Determann D, Petrou S, et al. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32(9):883–902.
   PubMed Web of Science ®Google Scholar
• Soekhai V, de Bekker-Grob EW, Ellis AR, et al. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019;37(2):201–226.
   PubMed Web of Science ®Google Scholar
• Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user’s guide. Pharmacoeconomics. 2008;26(8):661–677.
   PubMed Web of Science ®Google Scholar
• Hauber AB, González JM, Groothuis-Oudshoorn CGM, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19(4):300–315.
   PubMed Web of Science ®Google Scholar
• Reed Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for Discrete-Choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3–13.
   PubMed Web of Science ®Google Scholar
• Johnson FR, Özdemir S, Mansfield C, et al. Crohn's disease patients’ risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007;133(3):769–779.
   PubMed Web of Science ®Google Scholar
• Calvet X, Taxonera C, Ricart E, et al. P025 - Patient preferences for Crohn’s disease maintenance therapy: a discrete choice experiment. J Crohn’s Colitis. 2009;3(1):S21.
   Google Scholar
• Peake STC, Landy J, Hussein M, et al. Patient preference in choosing biological therapy in Crohn's disease. Inflamm Bowel Dis. 2011;17(7):E79.
   PubMedGoogle Scholar
• Lichtenstein DGR, Waters HC, Kelly J, et al. Assessing drug treatment preferences of patients with Crohn’s disease. Patient Patient-Center Outcomes Res. 2010;3(2):113–123.
   Web of Science ®Google Scholar
• Santos CHMD. Analysis of the factors related to anti-TNF alpha response in the treatment of Crohn’s disease. J Coloproctol (Rio De Janeiro). 2014;34(01):014–018.
   Google Scholar
• Payne K, Fargher EA, Roberts SA, et al. Valuing pharmacogenetic testing services: a comparison of patients’ and health care professionals’ preferences. Value Health. 2011;14(1):121–134.
   PubMed Web of Science ®Google Scholar
• Hedayat AS, Sloane NJA, Stufken J. Orthogonal arrays: theory and applications. Springer Science & Business Media; 1999.
   Google Scholar
• Street DJ, Burgess L, Viney R, et al. Designing discrete choice experiments for health care. In: Ryan M, Gerard K, Amaya-Amaya M, editors. Using discrete choice experiments to value health and health care. Dordrecht, the Netherlands: Springer Netherlands; 2008. p. 47–72.
   Google Scholar
• de Bekker-Grob EW, Hol L, Donkers B, et al. Labeled versus unlabeled discrete choice experiments in health economics: an application to colorectal cancer screening. Value Health. 2010;13(2):315–323.
   PubMed Web of Science ®Google Scholar
• Orme B. Sample size issues for conjoint analysis studies. Sequim: Sawtooth Software Technical Paper. 1998.
   Google Scholar
• Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology. 1994;106(2):287–296.
   PubMed Web of Science ®Google Scholar
• Bewtra M, Fairchild A, Gilroy E, et al. Inflammatory bowel disease patients’ willingness to accept medication risk to avoid future disease relapse. Am J Gastroenterol. 2015;110(12):1675–1681.
   PubMed Web of Science ®Google Scholar
• Fumery M, Savoye G, Pariente B, et al. Épidémiologie et histoire naturelle des maladies inflammatoires chroniques intestinales: 30 ans de registre EPIMAD. Hépato-Gastro Oncol Digest. 2018;25(2):145–152.
   Google Scholar